Zealand Pharma A/S is a biotechnology company, which engages in the discovery, design, and development of peptide based medicines. The firm is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The firm's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The firm operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.
Follow-Up Questions
What is Zealand Pharma A/S (ZLDPF)'s P/E Ratio?
The P/E ratio of Zealand Pharma A/S is N/A
What is the price performance of ZLDPF stock?
The current price of ZLDPF is 73.31, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Zealand Pharma A/S?
Zealand Pharma A/S belongs to Biotechnology industry and the sector is Health Care
What is Zealand Pharma A/S market cap?
Zealand Pharma A/S's current market cap is $3.3
Is Zealand Pharma A/S a buy, sell, or hold?
According to wall street analysts, 18 analysts have made analyst ratings for Zealand Pharma A/S, including 9 strong buy, 11 buy, 3 hold, 0 sell, and 9 strong sell
